Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jenny Shliozberg

Allergy & Immunology Brooklyn, NY Medical Doctor

NPI 1174603971 CMS profile 234911

1321 E 7Th St, Brooklyn, NY 11230

Open in the dashboard

General payments

$12,303

373 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$151,894 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Jenny Shliozberg of Brooklyn, NY is reported in the CMS Open Payments database as having received $12,303 across 373 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $151,894 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,290 64
2024 General $1,430 55
2023 General $1,003 33
2022 General $3,604 106
2021 General $1,338 39
2020 General $818 29
2019 General $1,819 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenny Shliozberg
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jenny Shliozberg were reported at $2,290. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jenny Shliozberg Allergy & Immunology median Middle half National median
2019 $1,819 $594 $163–$1,512 $163
2020 $818 $426 $106–$1,233 $114
2021 $1,338 $638 $157–$1,708 $132
2022 $3,604 $790 $205–$1,961 $149
2023 $1,003 $852 $220–$2,147 $160
2024 $1,430 $865 $203–$2,267 $164
2025 $2,290 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OptiNose US, Inc. $2,024 20 payments
  2. AstraZeneca Pharmaceuticals LP $1,518 20 payments
  3. BioCryst US Sales Co., LLC $1,378 35 payments
  4. Genzyme Corporation $1,155 34 payments
  5. GlaxoSmithKline, LLC. $959 31 payments
  6. Regeneron Healthcare Solutions, Inc. $844 23 payments
  7. Genentech USA, Inc. $796 73 payments
  8. CSL Behring $437 20 payments
  9. Pfizer Inc. $420 18 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $394 28 payments
  11. Other $2,378 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,529 369 payments
  2. Consulting Fee $1,500 1 payment
  3. Education $274 3 payments
Products named General payments · program years 2019–2025
  1. Xhance $2,024 20 payments
  2. Orladeyo $1,378 35 payments
  3. DUPIXENT Immunology $1,309 40 payments
  4. DUPIXENT Inflammation And Immunology $972 21 payments
  5. Xolair $717 62 payments
  6. TEZSPIRE $537 8 payments
  7. NUCALA Immunology $508 22 payments
  8. VTAMA $396 4 payments
  9. NUCALA Respiratory $358 8 payments
  10. HYQVIA $297 21 payments
  11. Other $3,548 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

661

Median for Allergy/ Immunology: 449

Drug cost

$472,376

Median for Allergy/ Immunology: $169,700

Branded share of claims

41.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 50 $195,936
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 33 $151,938
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 16 $59,620
Juluca Dolutegravir/Rilpivirine Brand 11 $36,161
Trulicity Dulaglutide Brand 11 $11,123
Breo Ellipta Fluticasone/Vilanterol Brand 12 $4,605
Dulera Mometasone/Formoterol Brand 12 $3,660
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 14 $2,353
Albuterol Sulfate Hfa Albuterol Sulfate Brand 51 $2,014
Ventolin Hfa Albuterol Sulfate Brand 20 $1,163

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$48,700

Medicare's payments for the services billed

Medicare patients

73

Average age 74

Services billed

2,554

53 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 67%
Ischemic heart disease 42%
Depression 37%
Heart failure 27%
Chronic kidney disease 25%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $218
  • Regeneron Pharmaceuticals, Inc. $117
  • GENZYME CORPORATION $72
$407 — —
Orladeyo
  • BioCryst US Sales Co., LLC $190
$190 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $153
$153 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
VTAMA
  • Dermavant Sciences, Inc. $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record